PROLOR Biotech Inc (NYSEMKT
BTH)
http://www.prolor-biotech.com/Home
PROLOR Biotech Initiates Pivotal Phase III Trial Of Its Longer-Acting Version Of Human Growth Hormone
http://finance.yahoo.com/news/prolor-biotech-initiates-pivotal-phase-113000834.html
PROLOR Biotech, Inc. (NYSE Mkt: PBTH), today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company's proprietary version of human growth hormone (hGH), in growth hormone deficient adults. PROLOR is developing hGH-CTP to provide growth hormone deficient adults and children with hGH therapy that may require only once-weekly or bi-monthly injections, rather than the daily injections required by current hGH therapy. The initiation of the Phase III clinical trial follows a set of successful Phase II trials showing that hGH-CTP has the potential to be effective when injected once weekly. In these studies, hGH-CTP was shown to be well tolerated and safe, and it met all clinical endpoints.
BTH)http://www.prolor-biotech.com/Home
PROLOR Biotech Initiates Pivotal Phase III Trial Of Its Longer-Acting Version Of Human Growth Hormone
http://finance.yahoo.com/news/prolor-biotech-initiates-pivotal-phase-113000834.html
PROLOR Biotech, Inc. (NYSE Mkt: PBTH), today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company's proprietary version of human growth hormone (hGH), in growth hormone deficient adults. PROLOR is developing hGH-CTP to provide growth hormone deficient adults and children with hGH therapy that may require only once-weekly or bi-monthly injections, rather than the daily injections required by current hGH therapy. The initiation of the Phase III clinical trial follows a set of successful Phase II trials showing that hGH-CTP has the potential to be effective when injected once weekly. In these studies, hGH-CTP was shown to be well tolerated and safe, and it met all clinical endpoints.
